

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (Cancelled)


2. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Currently amended) A compound of claim 33 ~~4~~, wherein R<sup>1</sup> is t-butyl and R<sup>2</sup> is unsubstituted or substituted phenyl.

9. (Currently amended) A compound of claim 33 ~~4~~ of the formula



wherein B and R<sup>2</sup> are as defined in claim 33 ~~4~~.

10. (Cancelled)

15. (Cancelled)

16. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Currently amended) A pharmaceutical composition comprising an effective amount of a compound of claim 33 and a pharmaceutically acceptable carrier.

25. (Previously Presented) A pharmaceutical composition comprising an effective amount of a compound of claim 33 and a pharmaceutically acceptable carrier.

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)


31. (Cancelled)

32. (Previously Presented) A compound as in claim 39 wherein B is optionally substituted pyridinyloxyphenyl, benzothiazolyloxyphenyl, benzothiazolylthiophenyl, pyrimidinyloxyphenyl, quinolinylthiophenyl, and phthalimidylmethylphenyl and R<sup>2</sup> is phenyl, substituted phenyl, pyridinyl or substituted pyridinyl.

33. (Previously Presented) A compound of formula I or a pharmaceutically acceptable salt thereof



wherein A is



wherein R<sup>1</sup> is C<sub>3</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, up to per-halosubstituted C<sub>1</sub>-C<sub>10</sub> alkyl or up to per-halosubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl;

B is phenyl, pyridinyl, or naphthyl, substituted by -M-L<sup>1</sup>; and is optionally substituted by one or more substituents independently selected from the group consisting of halogen, up to per-halosubstitution, and X<sub>n</sub>,

wherein n is 0–2 and each X is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>5'</sup>, -C(O)R<sup>5</sup>, -NO<sub>2</sub>, -OR<sup>5</sup>, -SR<sup>5</sup>, -NR<sup>5</sup>R<sup>5'</sup>, -NR<sup>5</sup>C(O)OR<sup>5'</sup>, -NR<sup>5</sup>C(O)R<sup>5'</sup>, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>6</sub>-C<sub>14</sub> aryl, C<sub>7</sub>-C<sub>24</sub> alkaryl, C<sub>3</sub>-C<sub>13</sub> heteroaryl, C<sub>4</sub>-C<sub>23</sub> alkheteroaryl, substituted C<sub>1</sub>-C<sub>10</sub> alkyl, substituted C<sub>2</sub>-C<sub>10</sub> alkenyl, substituted C<sub>1</sub>-C<sub>10</sub> alkoxy, substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl, up to per-halosubstituted C<sub>6</sub>-C<sub>14</sub> aryl, up to per-halosubstituted C<sub>3</sub>-C<sub>13</sub> heteroaryl and substituted C<sub>4</sub>-C<sub>23</sub> alkheteroaryl and -M-L<sup>1</sup>;

where X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>5</sup>, -C(O)R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>5'</sup>, -OR<sup>5</sup>, -SR<sup>5</sup>, -NR<sup>5</sup>R<sup>5'</sup>, -NO<sub>2</sub>, -NR<sup>5</sup>C(O)R<sup>5'</sup>, -NR<sup>5</sup>C(O)OR<sup>5'</sup> and halogen up to per-halosubstitution;

wherein R<sup>5</sup> and R<sup>5'</sup> are independently selected from H, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>6</sub>-C<sub>14</sub> aryl, C<sub>3</sub>-C<sub>13</sub> heteroaryl, C<sub>7</sub>-C<sub>24</sub> alkaryl, C<sub>4</sub>-C<sub>23</sub> alkheteroaryl, up to per-halosubstituted C<sub>1</sub>-C<sub>10</sub> alkyl, up to per-halosubstituted C<sub>2</sub>-C<sub>10</sub> alkenyl, up to per-halosubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl, up to per-halosubstituted C<sub>6</sub>-C<sub>14</sub> aryl and up to per-halosubstituted C<sub>3</sub>-C<sub>13</sub> heteroaryl,

wherein M is -O-, -S-, or -(CH<sub>2</sub>)-<sub>m</sub>

m = 1–3, and X<sup>a</sup> is halogen; and

L<sup>1</sup> is pyridinyl, quinolinyl or isoquinolinyl, optionally substituted by halogen up to per-halosubstitution and optionally substituted by Z<sub>n1</sub>,

wherein n1 is 0 to 3 and each Z is independently -CN, -CO<sub>2</sub>R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>5'</sup>, -C(O)NR<sup>5</sup>, -NO<sub>2</sub>, -OR<sup>5</sup>, -SR<sup>5</sup>, -NR<sup>5</sup>R<sup>5'</sup>, -NR<sup>5</sup>C(O)OR<sup>5'</sup>, -C(O)R<sup>5</sup>, NR<sup>5</sup>C(O)R<sup>5'</sup>, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>6</sub>-C<sub>14</sub> aryl, C<sub>3</sub>-C<sub>13</sub> heteroaryl, C<sub>7</sub>-C<sub>24</sub> alkaryl, C<sub>4</sub>-C<sub>23</sub> alkheteroaryl, substituted C<sub>1</sub>-C<sub>10</sub> alkyl, substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl, substituted C<sub>7</sub>-C<sub>24</sub> alkaryl or substituted C<sub>4</sub>-C<sub>23</sub> alkheteroaryl;

wherein if Z is a substituted group, it is substituted by the one or more substituents independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>5'</sup>, -OR<sup>5</sup>, -SR<sup>5</sup>, -NO<sub>2</sub>, -NR<sup>5</sup>R<sup>5'</sup>, -NR<sup>5</sup>C(O)R<sup>5'</sup> and -NR<sup>5</sup>C(O)OR<sup>5'</sup>, and

wherein R<sup>2</sup> is unsubstituted phenyl, unsubstituted pyridinyl, substituted phenyl or substituted pyridinyl

wherein if R<sup>2</sup> is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of halogen, up to per-halosubstitution, and V<sub>n</sub>,

wherein n = 0–3 and each V is independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>5'</sup>, -OR<sup>5</sup>, -SR<sup>5</sup>, -NR<sup>5</sup>R<sup>5'</sup>, -C(O)R<sup>5</sup>, -OC(O)NR<sup>5</sup>R<sup>5'</sup>, -NR<sup>5</sup>C(O)OR<sup>5'</sup>, -SO<sub>2</sub>R<sup>5</sup>, -SOR<sup>5</sup>, -NR<sup>5</sup>C(O)R<sup>5'</sup>, -NO<sub>2</sub>, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>6</sub>-C<sub>14</sub> aryl, C<sub>3</sub>-C<sub>13</sub> heteroaryl, C<sub>7</sub>-C<sub>24</sub> alkaryl, C<sub>4</sub>-C<sub>24</sub> alkheteroaryl, substituted C<sub>1</sub>-C<sub>10</sub> alkyl, substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl, substituted C<sub>6</sub>-C<sub>14</sub> aryl, substituted C<sub>3</sub>-C<sub>13</sub> heteroaryl, substituted C<sub>7</sub>-C<sub>24</sub> alkaryl and substituted C<sub>4</sub>-C<sub>24</sub> alkheteroaryl,

where if V is a substituted group, it is substituted by one or more substituents


independently selected from the group consisting of halogen, up to per-halosubstitution, -CN, -CO<sub>2</sub>R<sup>5</sup>, -C(O)R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>5</sup>, -NR<sup>5</sup>R<sup>5</sup>, -OR<sup>5</sup>, -SR<sup>5</sup>, -NR<sup>5</sup>C(O)R<sup>5</sup>, -NR<sup>5</sup>C(O)OR<sup>5</sup> and -NO<sub>2</sub>;  
wherein R<sup>5</sup> and R<sup>5</sup> are each independently as defined above.

**34. (Previously Presented)** A compound of claim 33 wherein one of the following combinations is satisfied:

R<sup>2</sup>= unsubstituted phenyl, B=phenyl and L<sup>1</sup> is pyridinyl, quinolinyl or isoquinolinyl,  
R<sup>2</sup>= unsubstituted phenyl, B=pyridinyl and L<sup>1</sup> is pyridinyl, quinolinyl or isoquinolinyl,  
R<sup>2</sup>= unsubstituted phenyl, B = naphthyl and L<sup>1</sup> is pyridinyl, quinolinyl or isoquinolinyl,  
R<sup>2</sup>= unsubstituted pyridinyl, B= phenyl and L<sup>1</sup> is pyridinyl, quinolinyl or isoquinolinyl,  
R<sup>2</sup>= unsubstituted pyridinyl, B= pyridinyl and L<sup>1</sup> is pyridinyl, quinolinyl or isoquinolinyl,  
R<sup>2</sup>= unsubstituted pyridinyl, B= naphthyl and L<sup>1</sup> is pyridinyl, quinolinyl or isoquinolinyl,  
R<sup>2</sup>= substituted phenyl, B=phenyl and L<sup>1</sup> is pyridinyl, quinolinyl or isoquinolinyl,  
R<sup>2</sup>= substituted phenyl, B=pyridinyl and L<sup>1</sup> is pyridinyl, quinolinyl or isoquinolinyl,  
R<sup>2</sup>= substituted phenyl, B = naphthyl and L<sup>1</sup> is pyridinyl, quinolinyl or isoquinolinyl,  
R<sup>2</sup>= substituted pyridinyl, B= phenyl and L<sup>1</sup> is pyridinyl, quinolinyl or isoquinolinyl,  
R<sup>2</sup>= substituted pyridinyl, B= pyridinyl and L<sup>1</sup> is pyridinyl, quinolinyl or isoquinolinyl, or  
R<sup>2</sup>= substituted pyridinyl, B= naphthyl and L<sup>1</sup> is pyridinyl, quinolinyl isoquinolinyl.


**38. (Cancelled)**

**39. (Currently amended)** A compound of Formula I or a pharmaceutically acceptable salt thereof



I

wherein A is



wherein  $R^1$  is  $C_3$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl, up to per-halosubstituted  $C_1$ - $C_{10}$  alkyl or up to per-halosubstituted  $C_3$ - $C_{10}$  cycloalkyl;

wherein  $R^2$  is phenyl substituted by one or more substituents independently selected from halogen, up to per-halosubstitution an  $V_n$ , wherein  $n=0-1$  and each  $V$  is independently  $-NO_2$ ,  $-NHC(O)CH_3$ ,  $-NH_2$ ,  $CH_3$ ,  $-OCH_3$  or  $-SO_2CH_3$ ;

B is phenyl, substituted by  $M-L^1$  and is optionally substituted by one or more substituents independently selected from the group consisting of halogen, up to per-halosubstitution and  $X_n$

wherein  $n$  is  $0-2$  and each  $X$  is independently selected from the group consisting of  $-CN$ ,  $-CO_2R^5$ ,  $-C(O)NR^5R^{5'}$ ,  $-C(O)R^5$ ,  $-NO_2$ ,  $-OR^5$ ,  $-SR^5$ ,  $-NR^5R^{5'}$ ,  $-NR^5C(O)OR^{5'}$ ,  $-NR^5C(O)R^5$ ,  $C_1$ - $C_{10}$  alkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_1$ - $C_{10}$  alkoxy,  $C_3$ - $C_{10}$  cycloalkyl,  $C_6$ - $C_{14}$  aryl,  $C_7$ - $C_{24}$  alkaryl,  $C_3$ - $C_{13}$  heteroaryl,  $C_4$ - $C_{23}$  alkheteroaryl, substituted  $C_1$ - $C_{10}$  alkyl, substituted  $C_2$ - $C_{10}$  alkenyl, substituted  $C_1$ - $C_{10}$  alkoxy, substituted  $C_3$ - $C_{10}$  cycloalkyl, up to per-halosubstituted  $C_6$ - $C_{14}$  aryl, up to per-halosubstituted  $C_3$ - $C_{13}$  heteroaryl and substituted  $C_4$ - $C_{23}$  alkheteroaryl and  $-M-L^1$ ;

where  $X$  is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of  $-CN$ ,  $-CO_2R^5$ ,  $-C(O)R^5$ ,  $-C(O)NR^5R^{5'}$ ,  $-OR^5$ ,  $-SR^5$ ,  $-NR^5R^{5'}$ ,  $-NO_2$ ,  $-NR^5C(O)R^5$ ,  $-NR^5C(O)OR^{5'}$  and halogen up to per-halosubstitution;

wherein  $R^5$  and  $R^{5'}$  are independently selected from H,  $C_1$ - $C_{10}$  alkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_6$ - $C_{14}$  aryl,  $C_3$ - $C_{13}$  heteroaryl,  $C_7$ - $C_{24}$  alkaryl,  $C_4$ - $C_{23}$  alkheteroaryl, up to per-halosubstituted  $C_1$ - $C_{10}$  alkyl, up to per-halosubstituted  $C_2$ - $C_{10}$  alkenyl, up to per-halosubstituted  $C_3$ - $C_{10}$  cycloalkyl, up to per-halosubstituted  $C_6$ - $C_{14}$  aryl and up to per-halosubstituted  $C_3$ - $C_{13}$  heteroaryl,

wherein M is -O-, -S-, -N( $R^5$ )-, -(CH<sub>2</sub>)<sub>m</sub>-, -C(O)-, -CH(OH)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -NR<sup>5</sup>C(O)-, -C(O)NR<sup>5</sup>, -O(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>m</sub>S-, -(CH<sub>2</sub>)<sub>m</sub>N( $R^5$ )-, -CHX<sup>a</sup>-, -CX<sup>a</sup><sub>2</sub>-, -S-(CH<sub>2</sub>)<sub>m</sub>- or -N( $R^5$ )(CH<sub>2</sub>)<sub>m</sub>-, m = 1-3, and X<sup>a</sup> is halogen; and

L<sup>1</sup> is pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, isoquinolinyl, phthalimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, benzofuryl, benzothienyl, indolyl, benzopyrazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl or benzisothiazolyl, optionally substituted by halogen up to per-halosubstitution and optionally substituted by Z<sub>n1</sub>,

wherein n1 is 0 to 3 and each Z is independently -CN, -CO<sub>2</sub>R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>5'</sup>, -C(O)NR<sup>5</sup>, -NO<sub>2</sub>, -OR<sup>5</sup>, -SR<sup>5</sup>, -NR<sup>5</sup>R<sup>5'</sup>, -NR<sup>5</sup>C(O)OR<sup>5'</sup>, -C(O)R<sup>5</sup>, NR<sup>5</sup>C(O)R<sup>5'</sup>,  $C_1$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_6$ - $C_{14}$  aryl,  $C_3$ - $C_{13}$  heteroaryl,  $C_7$ - $C_{24}$  alkaryl,  $C_4$ - $C_{23}$  alkheteroaryl, substituted  $C_1$ - $C_{10}$  alkyl, substituted  $C_3$ - $C_{10}$  cycloalkyl, substituted  $C_7$ - $C_{24}$  alkaryl or substituted  $C_4$ - $C_{23}$  alkheteroaryl;

wherein if Z is a substituted group, it is substituted by the one or more substituents independently selected from the group consisting of -CN, -CO<sub>2</sub>R<sup>5</sup>, -C(O)NR<sup>5</sup>R<sup>5'</sup>, -OR<sup>5</sup>, -SR<sup>5</sup>, -NO<sub>2</sub>, -NR<sup>5</sup>R<sup>5'</sup>, -NR<sup>5</sup>C(O)R<sup>5'</sup> and -NR<sup>5</sup>C(O)OR<sup>5'</sup>.

**40. (Cancelled)**